2014

Solos Endoscopy Sales Increase by More than 35% for the Month of October

BOSTON, Nov. 8, 2012 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company's sales for the month of October increased by more than 35%.  In addition, the Company expects to show a sales increase of more than 3% when it posts its third quarter financials for period ending September 30, 2012.

Solos Endoscopy's sales increased from $27,455 for month of October 2011 to $37,274 for October, 2012.  Solos management stated that sales for the month would have been greater; however, several orders scheduled to be shipped to tri-state hospitals have been pushed back to November due to Hurricane Sandy. 

Solos Endoscopy instruments are FDA approved.  The Company recently retained TUV SUD America, Inc. to complete its ISO 13485 Certification and Audit on its instruments including the MammoView®.  The Company previously engaged Expert Resource to prepare the Company for the final audit.  Expert Resource will attend the final audit, and help interpret any findings.  According to Expert Resource, their consultants maintain a 100% success rate of passing the final audit on the first attempt. Solos Endoscopy has posted its updated ISO 13485 CE Mark Schedule on its website, http://solosendoscopy.com/pdf/SNDY-ISO-13485-CE-Mark-Project-Schedule-October-2012.pdf.

Solos Endoscopy expects to post its third quarter financials on www.otcmarkets.com within the next two weeks.  The Company will also be releasing its "President's Report" for distribution to its shareholders in the next few weeks.

"We are very encouraged by the progress our team has made over the last few months.  We look for that trend to continue," stated Robert Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy is celebrating its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country.  For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.

Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact:
Solos Endoscopy, Inc.
(617) 360-9719

 

SOURCE Solos Endoscopy, Inc.



RELATED LINKS
http://www.solosendoscopy.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.